Comparative Pharmacology
Head-to-head clinical analysis: LISINOPRIL versus ZESTRIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LISINOPRIL versus ZESTRIL.
LISINOPRIL vs ZESTRIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor. It inhibits ACE, which converts angiotensin I to angiotensin II, a potent vasoconstrictor. This results in decreased plasma angiotensin II, leading to decreased vasoconstriction, reduced aldosterone secretion, decreased sodium and water retention, and lower blood pressure.
Lisinopril competes with angiotensin I for binding to angiotensin-converting enzyme (ACE), inhibiting its activity, thereby preventing conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This leads to decreased blood pressure, reduced aldosterone secretion, and decreased sodium and water retention.
Initial: 5-10 mg orally once daily. Maintenance: 10-40 mg orally once daily. Max: 80 mg/day.
10 mg orally once daily initially; titrate to 20-40 mg orally once daily. Maximum 80 mg/day.
None Documented
None Documented
Clinical Note
moderateLisinopril + Etacrynic acid
"The risk or severity of adverse effects can be increased when Lisinopril is combined with Etacrynic acid."
Clinical Note
moderateLisinopril + Bumetanide
"The risk or severity of adverse effects can be increased when Lisinopril is combined with Bumetanide."
Clinical Note
moderateLisinopril + Benzydamine
"The risk or severity of adverse effects can be increased when Lisinopril is combined with Benzydamine."
Clinical Note
moderateLisinopril + Estrone sulfate
Terminal half-life approximately 12 hours (range 11–13 hours); clinical context: once-daily dosing for hypertension and heart failure; accumulation occurs with renal impairment.
Terminal elimination half-life is about 12 hours for lisinopril; in heart failure, half-life may be prolonged. Steady-state achieved in 2-3 days.
Renal: 100% unchanged via glomerular filtration and tubular secretion; negligible biliary/fecal elimination.
Primarily renal (approximately 70% unchanged), with the remainder excreted as inactive metabolites via feces and urine.
Category D/X
Category C
ACE Inhibitor
ACE Inhibitor
"The serum concentration of Estrone sulfate can be decreased when it is combined with Lisinopril."